Fig. 1From: A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trialSchedule of visits and treatment. RECIST Response Evaluation Criteria in Solid TumorsBack to article page